ArticleMedical oncology (Northwood, London, England)2026
Gecko protein F2 inhibits tumor angiogenesis by suppressing the VEGF/MAPK/ERK signaling pathway.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The anti-tumor clinical effect of traditional Chinese medicine gecko is very prominent. A novel anti-tumor protein component F2 was isolated and purified from geckos by our group, and the aim of this study was to investigate its antitumor effects in vitro and in vivo and its mechanism of action by inhibiting angiogenesis. The proliferation of cells was determined by colony formation assay and MTT assay. The apoptosis of A549 cells was detected by flow cytometry, and the gene expression changes of cells was analyzed by RNA-seq technology. An H22 tumor-bearing mouse model was prepared, the tumor tissue was analyzed by CD31 immunohistochemical staining. The expression levels of target proteins were detected by Western blot. The proliferation of tumor cells A549 and BEL-7402 was significantly inhibited by F2, but the growth of normal cells L02 was not affected. F2 induces apoptosis in A549 cells and inhibits its migration. RNA-seq results showed that F2 significantly inhibited MAPK signaling pathway in A549 and BEL-7402 cells, and the related genes MEK2 and ERK were significantly down-regulated. The zebrafish thrombus model test showed that the extract of gecko has a significant inhibitory effect on thrombus formation in zebrafish. F2 showed a tumor inhibition rate of 42.24% in mice. A decrease in blood vessels around the tumor and in the tumor tissue was observed. The treatment resulted in a significant down-regulation of VEGF and p-ERK expressions, while a significant up-regulation of p-JNK. In conclusion, F2 has significant antitumor activity. One of its mechanisms of action is to suppress angiogenesis in tumor tissue and surrounding tissues by inhibiting the VEGF/ERK/MAP signaling pathway.
Indexed as
Identifiers
41652140What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.